CN107890117A - 一种浓缩乳清蛋白复合低聚肽营养粉 - Google Patents
一种浓缩乳清蛋白复合低聚肽营养粉 Download PDFInfo
- Publication number
- CN107890117A CN107890117A CN201710934686.5A CN201710934686A CN107890117A CN 107890117 A CN107890117 A CN 107890117A CN 201710934686 A CN201710934686 A CN 201710934686A CN 107890117 A CN107890117 A CN 107890117A
- Authority
- CN
- China
- Prior art keywords
- wpc
- parts
- powder
- oligopeptide
- wheat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 58
- 239000000843 powder Substances 0.000 title claims abstract description 37
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 title claims abstract description 16
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 58
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 57
- 241000209140 Triticum Species 0.000 claims abstract description 50
- 235000021307 Triticum Nutrition 0.000 claims abstract description 50
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 37
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 27
- 240000008042 Zea mays Species 0.000 claims abstract description 24
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 24
- 241000233866 Fungi Species 0.000 claims abstract description 23
- 239000012141 concentrate Substances 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 17
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims abstract description 16
- 240000003394 Malpighia glabra Species 0.000 claims abstract description 16
- 235000014837 Malpighia glabra Nutrition 0.000 claims abstract description 16
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims abstract description 14
- 235000009973 maize Nutrition 0.000 claims abstract description 14
- 230000029087 digestion Effects 0.000 claims abstract description 8
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 102000007544 Whey Proteins Human genes 0.000 claims description 10
- 108010046377 Whey Proteins Proteins 0.000 claims description 10
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 10
- 235000005822 corn Nutrition 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 108010068370 Glutens Proteins 0.000 claims description 8
- 235000021312 gluten Nutrition 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- 235000021119 whey protein Nutrition 0.000 claims description 6
- 239000004383 Steviol glycoside Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 229930182488 steviol glycoside Natural products 0.000 claims description 5
- 235000019411 steviol glycoside Nutrition 0.000 claims description 5
- 150000008144 steviol glycosides Chemical class 0.000 claims description 5
- 235000019202 steviosides Nutrition 0.000 claims description 5
- 239000005862 Whey Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 238000013329 compounding Methods 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 abstract description 37
- 230000035764 nutrition Effects 0.000 abstract description 33
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 abstract description 24
- 206010028980 Neoplasm Diseases 0.000 abstract description 22
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 201000010099 disease Diseases 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 9
- 208000002720 Malnutrition Diseases 0.000 abstract description 7
- 208000025865 Ulcer Diseases 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 230000001071 malnutrition Effects 0.000 abstract description 6
- 235000000824 malnutrition Nutrition 0.000 abstract description 6
- 208000015380 nutritional deficiency disease Diseases 0.000 abstract description 6
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 231100000397 ulcer Toxicity 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract description 2
- 230000005784 autoimmunity Effects 0.000 abstract description 2
- 208000019423 liver disease Diseases 0.000 abstract description 2
- 208000009928 nephrosis Diseases 0.000 abstract description 2
- 231100001027 nephrosis Toxicity 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 78
- 230000000694 effects Effects 0.000 description 61
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 53
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 37
- 229930003268 Vitamin C Natural products 0.000 description 37
- 235000019154 vitamin C Nutrition 0.000 description 37
- 239000011718 vitamin C Substances 0.000 description 37
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 36
- 230000006870 function Effects 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 102000004407 Lactalbumin Human genes 0.000 description 27
- 108090000942 Lactalbumin Proteins 0.000 description 27
- 229960003180 glutathione Drugs 0.000 description 26
- 108010035532 Collagen Proteins 0.000 description 25
- 102000008186 Collagen Human genes 0.000 description 24
- 229920001436 collagen Polymers 0.000 description 24
- 238000011160 research Methods 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 20
- 150000004676 glycans Chemical class 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 235000013305 food Nutrition 0.000 description 19
- 229920001282 polysaccharide Polymers 0.000 description 19
- 239000005017 polysaccharide Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 150000003254 radicals Chemical class 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 235000012000 cholesterol Nutrition 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000003078 antioxidant effect Effects 0.000 description 15
- 235000019197 fats Nutrition 0.000 description 15
- 239000003963 antioxidant agent Substances 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 241001506047 Tremella Species 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 9
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229920001503 Glucan Polymers 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000003064 anti-oxidating effect Effects 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000000050 nutritive effect Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 101800001982 Cholecystokinin Proteins 0.000 description 5
- 102100025841 Cholecystokinin Human genes 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010001831 LDL receptors Proteins 0.000 description 5
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 5
- 208000034189 Sclerosis Diseases 0.000 description 5
- 206010047623 Vitamin C deficiency Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229940107137 cholecystokinin Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 208000010233 scurvy Diseases 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 4
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 108010063045 Lactoferrin Proteins 0.000 description 4
- 102000010445 Lactoferrin Human genes 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 4
- 229940078795 lactoferrin Drugs 0.000 description 4
- 235000021242 lactoferrin Nutrition 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- -1 lactoalbumin Proteins 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000036186 satiety Effects 0.000 description 3
- 235000019627 satiety Nutrition 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 235000019710 soybean protein Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 2
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 2
- JCSJTDYCNQHPRJ-UHFFFAOYSA-N 20-hydroxyecdysone 2,3-acetonide Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(OC2C(C(O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 208000034767 Hypoproteinaemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 102000002070 Transferrins Human genes 0.000 description 2
- 108010015865 Transferrins Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- JCSJTDYCNQHPRJ-FDVJSPBESA-N beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-D-Xylp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-FDVJSPBESA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000008717 functional decline Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000035992 intercellular communication Effects 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002366 mineral element Substances 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- ABKNGTPZXRUSOI-UHFFFAOYSA-N xylotriose Natural products OCC(OC1OCC(OC2OCC(O)C(O)C2O)C(O)C1O)C(O)C(O)C=O ABKNGTPZXRUSOI-UHFFFAOYSA-N 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- TWNIBLMWSKIRAT-RWOPYEJCSA-N (1r,2s,3s,4s,5r)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound O1[C@@]2([H])OC[C@]1([H])[C@@H](O)[C@H](O)[C@@H]2O TWNIBLMWSKIRAT-RWOPYEJCSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- XJECNSWAHCMYNZ-UHFFFAOYSA-N C=C.[Fe].[Na] Chemical group C=C.[Fe].[Na] XJECNSWAHCMYNZ-UHFFFAOYSA-N 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010001817 Endo-1,4-beta Xylanases Proteins 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 101000693916 Gallus gallus Albumin Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000988577 Homo sapiens 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000908178 Tremella fuciformis Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000005906 dihydroxylation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 231100000880 dysequilibrium Toxicity 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108010050792 glutenin Proteins 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 108010062951 hypertensive factor Proteins 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 235000020905 low-protein-diet Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- HLNRBHDRGMNBEG-UHFFFAOYSA-N nitrous acid Chemical compound ON=O.ON=O HLNRBHDRGMNBEG-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000006555 post-translational control Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
- A23L31/10—Yeasts or derivatives thereof
- A23L31/15—Extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种浓缩乳清蛋白复合低聚肽营养粉,主要包括如下以重量份计的原料:浓缩乳清蛋白55~70份、银耳粉7~12份、针叶樱桃粉7~12份、小麦低聚肽2~6份、玉米低聚肽2~6份、酵母‑β葡聚糖0.5~1.7份、低聚木糖3~6份。本发明的有益效果为:本发明配伍科学合理,且协同增效,从不同角度改善临床营养不良症状,即解决了营养消化和吸收的问题,促进手术、溃疡等病人的康复,又能改善肠道功能、增强自身免疫力,并能改善血液健康,降低感染风险和并发症的发生率,适合糖尿病、肾病、肝病、肿瘤、放化疗、心血管疾病、烧伤、感染等多种疾病的临床营养支持。
Description
技术领域
本发明涉及食品加工技术领域,主要是一种浓缩乳清蛋白复合低聚肽营养粉。
背景技术
近年来,我国非常重视临床营养产业的发展,于2013年出台《特殊医学用途配方食品通则》,首次明确特殊医学用途配方食品(FSMP)的法律地位,并于2016年7月1日实施《特殊医学用途配方食品注册管理办法》。临床营养在治疗疾病的过程中起着重要作用,患者营养状况的好坏直接影响着创伤的愈合与疾病的恢复,营养状况良好可延缓某些疾病的发生和发展。
临床营养,指为治疗或缓解疾病,增强治疗的临床效果,而根据营养学原理采取的膳食营养措施。临床营养支持方法主要分为肠外和肠内两种途径。肠内营养是经胃肠道提供代谢需要的营养物质及其他各种营养素的营养支持方式,要求患者肠胃功能健全或部分健全。肠内营养制剂按平衡性可分为能全面提供人体必需营养物质的平衡性制剂、针对某种特定疾病或特殊人群消化特征和所需营养而配制的疾病使用型制剂和仅以某种或某类营养素为主的组件型制剂。肠内营养制剂按氮源可分为整蛋白型、短肽型和氨基酸型,可以保证肠胃功能不同的病人都能有效地进行对蛋白质和其他营养物质的消化吸收。
在国外,临床营养已经有五十多年的发展历史,已经发展相对成熟,临床营养作为辅助医疗手段可以有效地支持病人的治疗和恢复。2014年,全球临床营养制剂市场规模为389亿美元,近四年年均增长率稳定在6-7%,并逐渐趋于平缓。其中美国欧洲市场占到全球市场一半以上,亚太地区中日本的市场规模最大,占全球20%左右,而其他亚太地区国家的临床营养制剂消费较少。目前我国受整体临床诊断水平的影响,医学界与大众对临床营养学的认知程度与使用程度较低。导致临床营养支持广泛推行的时间较短,临床营养学科的建设和临床营养的应用仍处于探索和发展的初期阶段,目前我国普遍存在患者缺乏有效的营养治疗情况。
近几年来,我国临床营养市场保持较稳定快速的增长,据北京国研中讯经济信息咨询中心调查数据显示,2014年,我国临床营养产品市场规模为115.5亿元,近四年的年均增长稳定在18%左右,肠内营养规模29亿左右,近几年复合增速超过30%,占比仅四分之一,这与国外肠内营养占比超过80%相比产品结构差异巨大,未来肠内营养仍将保持快速增长。
市场常见的产品多为提供蛋白质和其他基础营养素,且大部分产品复配了大豆蛋白,大豆蛋白的生物价不及乳清蛋白,更不及低聚肽制剂,在吸收利用方面不够理想。另外,临床上对提升免疫、促进伤口愈合、改善胃肠道功能等方面有极大的需求,而目前市场多数产品都不能满足,且口感较差,服用者依从性不佳。本发明针对上述问题,进行了临床调研,设计了科学的营养配方,完美解决上述问题。
发明内容
本发明的目的在于克服现有技术存在的不足,而提供一种浓缩乳清蛋白复合低聚肽营养粉。
本发明的目的是通过如下技术方案来完成的。这种浓缩乳清蛋白复合低聚肽营养粉,主要包括如下以重量份计的原料:浓缩乳清蛋白55~70份、银耳粉7~12份、针叶樱桃粉7~12份、小麦低聚肽2~6份、玉米低聚肽2~6份、酵母-β葡聚糖0.5~1.7份、低聚木糖3~6份。
本发明以浓缩乳清蛋白(将乳清通过低温超滤和喷雾干燥制成的天然乳清蛋白浓缩物,该产品含卵磷脂。它具有极高的营养价值,是运动营养食品和其他蛋白质强化配方食品的理想原料。在冷水和温水中它的润湿性良好,溶解迅速。)、银耳粉(经提取、浓缩、干燥精制而成)、针叶樱桃粉(经提取、浓缩、干燥精制而成)、小麦低聚肽(以谷朊粉为原料、经过定向酶切及特定的小肽分离技术获得的小分子多肽类混合物,主要成分是由2~6个氨基酸分子构成的小肽)、玉米低聚肽(经过一系列酶解后的产物,它是由大量小分子量短肽组成,分子量集中在1000以下)、酵母-β葡聚糖(以酿酒酵母为原料,经提取、酸碱处理、喷雾干燥等步骤生产而成)、低聚木糖(以小麦秸秆或玉米秸秆为原料采用蒸汽爆破法或高压蒸煮法,经木聚糖酶酶解生产而成)为原料,以等量递加原则混合均匀。
本发明的有益效果为:本发明以乳清蛋白为核心,提供优质蛋白营养,复配小麦低聚肽和玉米低聚肽,可以直接吸收,转运速度快、耗能低、不易饱和,同时能够消除与游离氨基酸的吸收竞争,弥补乳清蛋白质和氨基酸所不具备的特点;而针叶樱桃是天然维生素C的来源,用于此处可促进消化吸收后的氨基酸、小肽类合成胶原蛋白,对于术后伤口恢复大有益处;银耳粉则富含多糖成分,可以修复胃黏膜,促进伤口愈合,可帮助消化道出血和手术人群的恢复,改善胃部疾病患者的消化吸收功能;酵母-β葡聚糖会让食物黏性增加、胃排空的速度减慢,进而增加了进餐时的满足感以及餐后的饱腹感,还可以刺激肠促胰酶肽(CCK)的释放,改善人体消化吸收功能,并刺激小肠蠕动的作用;低聚木糖有很强的增殖肠道益生菌的功能,对双歧杆菌、乳酸菌等益生菌有高选择性增殖效果,但对大肠杆菌、肠球菌、梭状芽孢杆菌等病原菌则有明显的抑制作用,全面改善肠道功能,改善便秘和腹泻症状。本发明配伍科学合理,且协同增效,从不同角度改善临床营养不良症状,即解决了营养消化和吸收的问题,促进手术、溃疡等病人的康复,又能改善肠道功能、增强自身免疫力,并能改善血液健康,降低感染风险和并发症的发生率,适合糖尿病、肾病、肝病、肿瘤、放化疗、心血管疾病、烧伤、感染等多种疾病的临床营养支持。
本发明为冲调食品,在水中能均匀快速分散(市场同类产品冲调多抱团,不易溶解),服用方便。适合食欲低下、或有进食难度和消化功能不健全的人群服用,吸收快速,营养丰富,功效独特,制成不同实施案例后,口感上佳,大大提升服用人群的依从性,较市场同类产品有明显的优势。
具体实施方式
下面将结合实施例对本发明做详细的介绍:
本发明所述的这种浓缩乳清蛋白复合低聚肽营养粉,主要包括如下以重量份计的原料:浓缩乳清蛋白55~70份、银耳粉7~12份、针叶樱桃粉7~12份、小麦低聚肽2~6份、玉米低聚肽2~6份、酵母-β葡聚糖0.5~1.7份、低聚木糖3~6份。不仅含有丰富的完全蛋白营养,还复配了多种功能因子,主要为低蛋白血症、营养不良、免疫力低下等人群提供优质可靠的营养支持。各原料的具体要求见下表。
原料名称 | 指标成分 | 质量要求 |
浓缩乳清蛋白 | 蛋白质 | ≥80% |
银耳粉 | 多糖 | ≥30% |
针叶樱桃粉 | 维生素C | ≥5% |
小麦低聚肽 | 蛋白质、低聚肽 | 蛋白质≥90%,低聚肽≥75% |
玉米低聚肽 | 蛋白质、低聚肽 | 蛋白质≥80%,低聚肽≥75% |
酵母-β葡聚糖 | β葡聚糖 | ≥80% |
低聚木糖 | 低聚木糖 | ≥95% |
本发明的机理:
1浓缩乳清蛋白及其功能
乳清蛋白在营养学中被认为是“蛋白之王”,是乳蛋白的主要成分,富含人体需要的所有必需氨基酸。具有纯度高、氨基酸配比恰当、极易被人体消化吸收,含有生物活性多肽,如乳球蛋白、乳白蛋白、免疫球蛋白、乳铁蛋白和多种多肽等诸多优点,能有效改善营养状况,是临床各种治疗饮食或管喂饮食优质蛋白质的最好来源。本发明所用浓缩乳清蛋白是将乳清通过低温超滤和喷雾干燥制成的天然乳清蛋白浓缩物(WPC),该产品含卵磷脂。它具有极高的营养价值,是运动营养食品和其他蛋白质强化配方食品的理想原料。在冷水和温水中它的润湿性良好,溶解迅速。
1.1维持和提高机体免疫力
研究证实,营养对免疫机能有重要影响,乳清蛋白提高还原型谷胱甘肽(GSH)水平,帮助维持和提高免疫力。GSH是免疫系统需要抗氧化剂,疾病中会导致其下降。乳清蛋白保持良好营养,使疾病治疗和康复达最佳状态。
1.2抗自由基,延缓衰老
乳清蛋白包含乳铁蛋白,促进氧合作用和对抗自由基。乳铁蛋白是转铁蛋白家族成员。转铁蛋白产生能量和调控红细胞、血红蛋白生成。
1.3维持肾功能
终末期肾衰蛋白质营养不良相当常见,6%~8%维持性血透有严重营养不良,33%有轻到中度营养不良。慢肾衰透析前,多严格控制蛋白质摄入量,长期低蛋白饮食,尿蛋白丢失,最终严重蛋白营养不良,组织蛋白分解加速,为死亡重要原因。维持性透析因代谢和内分泌紊乱、食欲不振和恶心呕吐、营养吸收障碍,透析不充分、不良反应和丢失等,有明显营养摄入不足和丢失,导致蛋白合成减少而分解增加。血透可诱导分解代谢加速。故成年透析者食物蛋白需求量比普通成人要高。
1.4促进创伤愈合
机体损伤和手术伤口愈合需要足够的高质量蛋白质,它是上皮生长修复必需的物质。蛋白质摄入不足,或摄入质量低都会延长损伤的愈合,甚至不愈合。乳清蛋白为优质蛋白,其生物利用价最高,是在烧伤和外科治疗中最优先使用的蛋白质。乳铁蛋白能调节免疫反应,为术后患者提供保护。短肠综合征患者给予乳清蛋白制剂后,可以促进创伤的愈合。
1.5防治“四高症”
防治高糖血症:乳清蛋白含丰富亮氨酸(Leu),能刺激胰岛素分泌,有效利用自身胰岛素,控制血糖。糖尿病患者一般食欲佳,食用乳清蛋白后,能产尘饱腹感,可减少“三多一少”症状。在为患者提供均衡适量优质蛋白质的同时,不致吸收过多的能量,并改善血糖而控制病情,延缓和防止并发症的发生和发展。
防治高血压:高血压病在心血管疾病中最为常见,因可引起动脉粥样硬化,继而使血管弹性下降,管腔狭窄,造成心脏、大脑等重要器官缺血缺氧,成为心脑血管病的主要危险因素。乳清蛋白为高血压患者最佳蛋白质补充品,对减低血压,减少并发症有积极作用。
防治高血脂:高脂血症表现为血浆多种脂质浓度超过正常。随着生活水平的提高,高脂血症已成为心血管疾病危险因素之一。高脂血症在补充乳清蛋白时,不会因能量摄入过多而致超重或肥胖,也不会因为饱和脂肪过多而使血胆固醇增高,有利于高脂血症患者降低血脂,预防并发症的发生。
1.6减肥
乳清蛋白几乎不含脂肪和碳水化合物,是低能或低脂饮食。高质量乳清蛋白含丰富亮氨酸(Leu)以保护瘦体组织,减少脂肪合成。乳清蛋白比鸡蛋蛋白和大豆蛋白含有更多Leu。通过减缓血糖吸收,稳定血糖,降低胰岛素,减少饥饿感,使机体更容易利用脂肪产生的能量。添加乳清蛋白,体重监测有明显差别,乳清蛋白可促进减重和维持标准体重。
1.7防治心脑血管疾病
最影响心脑血管疾病发病率的危险因素是高血压和高血脂,乳清蛋白活性肽可以减少这些危险因素不良影响。其抗氧化作用,从整体上保护心血管健康,提高心血管的机能,预防心血管疾病。
1.8防治脂肪肝
肝脏是中性脂肪合成、转运与利用的主要器官,脂肪合成与转运平衡失调,则脂肪在肝内堆积成脂肪肝。磷脂是合成脂蛋白必需材料,如磷脂下降或合成磷脂原料不足,特别是胆碱或参加合成胆碱蛋氨酸缺乏,影响脂蛋白在肝脏的合成和输出,形成脂肪肝。研究证明,长期高糖、高脂肪和肥胖是形成脂肪肝常见原因。乳清蛋白为肝脏提供蛋白原料,在药物治疗同时能促进肝脏细胞恢复和新生,防止变性肝细胞坏死而发展为肝硬化。其低脂肪含量能减少肝脏对脂肪代谢负担,是脂肪肝患者理想蛋白质食品。
1.9防治肝硬化
肝硬化是各种原因长期或反复损害肝脏而致弥漫性纤维组织增生和肝细胞结节状再生,肝正常结构破坏,形成肝脏变硬的严重疾病。医学证明,食物中缺乏蛋白质和胆碱能抗脂肪肝因子时,可损害肝脏并诱发肝硬化。乳清蛋白含高质量蛋白质,在满足患者对优质蛋白需求时不会因脂肪摄入过多,超过肝脏代谢能力,使脂肪沉积于肝内,造成肝功能进一步损害,血浆蛋白含量较低又有腹水的患者,提供优质蛋白尤其重要。
1.10防治消化性溃疡
蛋白质是组织细胞修复的原料,只有充足蛋白溃疡面才能修复。乳清蛋白为溃疡面修复良好的来源,能迅速促进溃疡面的愈合,保护胃黏膜屏障不受损害,增强胃黏膜抵抗力,同时蛋白摄入又对胃酸起到缓冲作用,在不增加胃代谢负担的同时促进溃疡面愈合。
1.11有助于癌症患者康复
癌症患者在化疗或放疗过程中,往往会因为恶心、呕吐和食欲不佳等因素,使每天摄入的营养不足,导致体重下降、肌肉组织丢失和蛋白质-能量营养不良。乳清蛋白因其易消化、对机体无刺激的优点,为癌症患者蛋白质良好来源。补充乳清蛋白可维持细胞高GSH浓度和提高细胞抗氧化防御能力,以促进对致癌物解毒作用。在动物和体外实验结果显示,乳清蛋白可以抑制某些癌细胞增长,如前列腺癌、乳腺癌、结肠癌等。与喂酪蛋白大鼠相比,喂养乳清蛋白大鼠肿瘤发生率降低近50%;与喂养大豆蛋白相比,肿瘤发生明显降低。乳清螯合铁离子的能力有助于抗癌。作用机制为乳清蛋白有很强抗氧化活性,因为半胱氨酸(Cys)含量高有助于GSH合成,而GSH是公认的细胞内强抗氧化剂。Cys含巯基,起到还原剂作用,防止细胞组织氧化和损伤。抗氧化剂GSH在其还原态时效果最强。可以直接用乳清蛋白作为Cys来源来提高细胞内GSH。
1.12有助于HIV治疗
营养不良而导致免疫功能障碍的营养性获得免疫缺乏综合征(HIV)已引起普遍重视,对于人和动物必需的重要营养素蛋白质和氨基酸与动物机体免疫机能关系已逐渐成为研究的重点。用分离纯乳清蛋白对HIV进行辅助治疗的研究提示,GSH明显不足的HIV感染患者,给予富含Cys乳清蛋白,6个月后可显著和持续增加血清GSH水平,并可达到正常水平。通常HIV患者细胞GSH含量降低,高水平GSH明显减慢病毒复制过程,导致病毒活性实质性下降,增加HIV患者生存期限。
2银耳及其功能
银耳(Tremella fuciformis)营养丰富,食味鲜美,不但是营养价值很高食用菌,也是药用价值较高药用菌,是世界公认保健品。我国银耳资源丰富,为开发应用银耳提供有利条件。随着银耳栽培业迅速发展及应用范围拓宽,对银耳营养成分及在医疗保健作用方面研究也逐步深入。银耳多糖(Tremella polysaccharides,TP)为银耳重要活性成分,其功能特性越来越受到关注。
2.1免疫调节、抗肿瘤作用
多年来,科学家们发现银耳多糖参与了细胞的各种生命现象的调节,如免疫细胞间信息的传递和感受、激活免疫细胞和提高机体的免疫功能等。通过这种参与,银耳多糖不仅可以借助增强宿主免疫功能而发挥抗肿瘤作用,还能通过直接作用于肿瘤细胞或诱导肿瘤细胞凋亡等途径直接杀伤肿瘤细胞。
2.2降血糖、降血脂作用
有研究表明,银耳多糖能够调节糖代谢酶的活性,促进胰岛分泌胰岛素抑制糖异生,促进外周组织对葡萄糖的利用,从而达到降血糖的作用。银耳多糖可以通过束缚和吸附血液中脂类促进胆固醇排出,阻断其在肝肠循环,达到降低血脂的效应。
2.3防治心血管疾病
研究表明,银耳多糖能明显延长血栓的形成时间,降低血小板勃附率和血液勃度,达到防治心血管疾病的作用。
2.4抗溃疡作用
银耳多糖可明显抑制大鼠应激型胃溃疡的形成,促进醋酸型胃溃疡的愈合,对胃酸分泌和胃蛋白酶活性并无影响。利用银耳多糖治疗十二指肠溃疡124例疗效观察,近期有效率达98.6%,近期愈合率达79.03%。
2.5抗凝血、促进创伤愈和作用
银耳多糖可通过影响内源性凝血系统,延长部分凝血酶时间而实现抗凝血作用。此外,银耳多糖对受试大鼠创伤有保护创面、预防感染作用,可以使创伤沿生理修复途径顺利进行,从而达到Ⅰ期愈合的效应
3针叶樱桃及其功效
针叶樱桃从1946年被发现每100克含有1800~4000mg超高量之维生素C后,引起科学界极大关注。针叶樱桃是目前种植的植物中维生素C含量最高的,每100g果中维C含量是柠檬的35倍,草莓的17倍,也比被认为维生素C极高的番石榴高11倍,是名副其实的“维生素C之王”,同时还含有维A、维B1、维B2、铁、钙等元素,维生素C是维持人体生命不可欠缺的重要成份,具有防治坏血酸的功能,所以又叫抗坏血酸(ascorbic acid),是一种水溶性的维生素。它能够防感冒,防坏血病,改善人体抵抗能力,对美容以及癌症有一定功效。在保健、饮料、美容方面有广泛的应用。
3.1抗氧化及清除自由基作用
自由基(free radical)是机体反应产生的有害物质,具有很强的氧化性,可损害机体的组织和细胞,从而造成一系列的慢性疾病。维生素C是一种水溶性的自由基清除剂,在体内可以清除·OH,R·和O2-等自由基,在抗氧化中起到重要的作用。谷胱甘肽(glutathione,GSH)是含有巯基的小肽类物质,具有抗氧化和解毒的作用。GSH有还原型(G-SH)和氧化型(G-S-S-G)两种形式,其中谷胱甘肽还原酶(glutathione reductase)催化两种物质之间的相互转化。在机体内,许多含有巯基的蛋白质和酶需要有巯基(-SH)才能发挥作用,而巯基容易受到如自由基H2O2等一些有害物质的氧化,从而使细胞受损、体内代谢受阻等。GSH自身可以被自由基氧化,保护其他蛋白和酶免遭自由基的破坏,起到抗氧化的作用。体内红细胞中GSH的含量较多,GSH可以保护红细胞膜上的蛋白的巯基处于还原态,防治溶血;可以保护血红蛋白,防止血红蛋白被自由基和过氧化物氧化成高铁血红蛋白,从而保障血红蛋白的输氧能力。维生素C为谷胱甘肽提供H,从而不断地补充体内的GSH,使其发挥抗氧化的作用。
许多研究表明,体内GSH的含量下降易使细胞膜受损,这与脂类过氧化有关。细胞膜上的不饱和脂肪酸易受到自由基、过氧化物等物质的氧化而形成脂质过氧化物,从而使细胞膜受损。GSH可以直接清除自由基,防止不饱和脂肪酸被氧化。另一方面,GSH可以抑制脂质过氧化的发生。过去的研究认为GSH可以将脂类的过氧化物还原成不饱和脂肪酸,这一过程是在谷胱甘肽过氧化物酶(GSH-Px)的作用下进行的。维生素C可以不断补充机体内的GSH,与GSH在抗脂类过氧化中共同发挥作用。
3.2促进胶原蛋白合成
维生素C在胶原蛋白合成方面的研究胶原蛋白(collagen)是人体内含有的最丰富的蛋白质,主要存在于人体皮肤、骨骼、牙齿、内脏(包括心、胃、血管)等部位,其功能是维持皮肤和组织器官的形态和结构,也是修复各损伤组织的重要原料物质。胶原蛋白包括很多类型,有Ⅰ,Ⅱ,Ⅲ,Ⅳ型等,其中Ⅰ型占到了全部胶原蛋白含量的90%以上。维生素C在胶原蛋白合成的过程中起到重要的作用。研究表明,增加维生素C可以使Ⅰ,Ⅲ型胶原蛋白mRNA的含量升高,利于胶原蛋白基因的表达,可以增强I,Ⅲ型mRNA的稳定性。另外,维生素C的含量升高能够抑制Ⅳ型胶原蛋白基因的表达。对于维生素C在胶原蛋白翻译后调控中的作用,维生素C是维持脯氨酸-4-羟化酶(pmlyl-4-hygroxylase,PH)活性必须的辅因子之一,PH在胶原蛋白的合成过程中将多肽链中的第4号C上的脯氨酸羟化成羟脯氨酸。羟脯氨酸对胶原蛋白的折叠,维持三级结构具有重要的作用。缺乏维生素C,PH将失去其活性,胶原蛋白就无法正确折叠。另外胶原蛋白肽链中的羟脯氨酸是由脯氨酸经过赖氨酸羟化酶(lysylhydroxylase,LH)的作用而形成的,该酶的活性也需要维生素C。羟赖氨酸在纤维胶原分子内能形成稳定的铰链结构,胶原蛋白是糖蛋白,羟赖氨酸的残基也是糖类的结合位点。胶原蛋白合成过程中的羟化反应非常重要,如果缺少维生素C就会产生严重的后果,如白血病。
3.3抗动脉粥状硬化
胆固醇(cholesterol)广泛存在于动物体内,尤其以脑及神经组织中最为丰富,在肾、脾、皮肤、肝和胆汁中的含量也很高。胆固醇是动物组织细胞中不可缺少的重要物质,它不仅参与细胞膜的形成,而且是合成胆汁酸、维生素D以及甾体激素的原料。但是过多的胆固醇就会对机体造成严重影响,如胆结石、动脉粥样硬化等。维生素C在胆固醇的代谢中有至关重要的作用。通过研究维生素C对皮肤成纤维细胞低密度脂蛋白受体(LDL-R)活性中发现,维生素C可以增强LDL-R基因的表达。人体内2/3的胆固醇存在于LDL中,LDL的降解是由细胞膜上的LDL-R介导的。LDL-R与LDL结合并介导LDL被细胞内吞,然后LDL在肝脏内代谢掉,胆固醇代谢形成胆汁酸并排出体外。胆固醇转变为胆汁酸先将环状部分羟基化,然后侧链分解即可形成胆汁酸,其中羟基化过程需要维生素C,缺少维生素C胆固醇无法转变为胆汁酸。在胆固醇的合成过程中,3-羟基-3-甲基戊二酰辅酶A还原酶(HMG-CoA还原酶)是合成胆固醇过程中的一个重要酶,维生素C可以抑制的HMG-CoA还原酶的活性,从而抑制胆固醇的合成。维生素C通过分解和合成两个途径共同调节胆固醇在机体内的含量,从而减少过量的胆固醇对机体造成的危害,在抗动脉粥样硬化中发挥着重要作用。
3.4抗坏血病
坏血病(scurvy)是由于缺乏维生素C而引起的疾病。早在几百年前人们就知道该疾病,但由于当时人们对于坏血病的发病原因不清楚,所以死亡率非常高。在18世纪,坏血病多发于远洋航海的水手、长期困战的士兵、长期缺乏新鲜水果和蔬菜的地区等。苏格兰海军军医詹姆斯·林德发现此病与饮食有关,英格兰探险家詹姆斯·库克进一步发现饮用橘子汁、柠檬汁后,可治疗和预防坏血病,但当时并不知道是什么物质产生作用。直到1912年波兰科学家卡西米尔·冯克阐明了维生素的概念,人们才确定该病是由于缺乏维生素C而引起的。坏血病的临床表现主要反映了维生素C在胶原蛋白合成过程中发挥的重要作用。特定的组织和毛细血管的脆弱主要是在胶原蛋白合成过程中脯氨酸羟化过程受阻,从而导致胶原蛋白无法合成。胶原蛋白归于结缔组织,是骨及毛细血管等的重要组成部分,而结缔组织是伤口愈合的第一步,所以胶原蛋白合成受阻就会出现毛细血管破损、瘀血、紫癜、牙龈出血、伤口愈合延迟、骨质脆弱、关节疼痛等症状,严重情况则会导致死亡。维生素C是胶原脯氨酸羟化酶的辅因子,缺少维生素C就会导致脯氨酸无法形成羟脯氨酸,影响胶原蛋白的合成。对于坏血病患者补充适量的维生素C就可以治疗坏血病。
3.5抗癌作用
癌症(cancer)是当今人类的第一大死因,治疗癌症也是世界的一个难题,维生素C在防治癌症方面也有重要的意义。诱发癌症的原因很多,包括基因突变,自由基对细胞的损伤,物理化学因素的诱导等。康奈尔大学教授C.Y.Lee等发现维生素C可以消除过氧化氢,防止细胞的癌变。其中维生素C对过氧化物诱发的抑制缺口衔接点细胞间交流(gap-junctionintercellular communication,GJIC)有预防作用。GJIC是维持正常细胞生长所必需的,与抑制癌症发生的过程尤其是与引发肿瘤紧密相关。过氧化氢是一种肿瘤引发剂,它通过改变一种特殊蛋白质-间隙连接蛋白43(connexin43)来抑制GJIC,从而诱导细胞的癌变。当用维生素C处理大鼠肝脏上皮细胞时,研究人员发现过氧化氢诱发的GJIC抑制作用被制止了。亚硝酸盐(nitrite)是世界公认的致癌物质,能够诱发多种癌症。研究表明,亚硝酸盐可以和机体内代谢产生的胺化合物形成亚硝酸胺而诱发癌症,维生素C可以阻断该途径,从而抑制癌症的发生。紫外辐射会导致DNA的损伤,诱发细胞的癌变。通过研究不同浓度维生素C对DNA紫外损伤的影响中发现,低于0.35mmol/L的维生素C对紫外线诱发的DNA损伤具有明显的保护作用并且保护效果随着其浓度的增大越来越好,0.35m mol/L时保护效果最佳。当维生素C的浓度高于0.35m mol/L时,维生素C不仅没有保护反而促进了DNA的损伤,DNA被损伤的程度随着维生素C浓度的增加而增加。DNA的水溶液在有氧的情况下经过紫外线的照射会产生自由基,自由基会破坏DNA,使其双链断裂,空间结构发生改变等。维生素C可以清除自由基,保护DNA免遭自由基的破坏。
4小麦低聚肽
近年来,生物活性肽的功能性质和应用引起了人们的广泛关注,研究指出,低聚肽比蛋白质更易消化,吸收也比氨基酸吸收速度快。低聚肽进入消化道后不需要消化,可以直接吸收,转运速度快、耗能低、不易饱和,同时能够消除与游离氨基酸的吸收竞争,这是原蛋白质和氨基酸所不具备的。我国是小麦生产大国,小麦资源丰富,从小麦中提取生物活性肽成为了人们关注的焦点。小麦低聚肽来源于小麦蛋白,成本低、加工性能好,是一种优良的营养补充剂,具有极大的市场开发利用价值。小麦低聚肽是以谷朊粉为原料、经过定向酶切及特定的小肽分离技术获得的小分子多肽类混合物,主要成分是由2~6个氨基酸分子构成的小肽,味苦、水溶性好、分散稳定、易吸收、生物活性强等。小麦低聚肽中氨基酸含量均衡,几乎与小麦蛋白一样,其中谷氨酸的含量最高,大部分以谷氨酰胺的形式存在。
4.1抗氧化
小麦低聚肽是一种抗氧化肽,可以很好地清除体内自由基,保护细胞的氧化应激。小麦低聚肽能够增强抗氧化酶活性,抑制脂质过氧化,加速体内自由基清除,同时有关体外抗氧化实验表明小麦低聚肽具有体外还原能力。关于小麦低聚肽抗氧化原理,国内外有不同的观点。肽的抗氧化活性的强弱与某氨基酸的组成和结构有关。研究发现,抗氧化肽优先与脂肪酸自由基结合,使自由基链式反应中止,从而抑制脂质过氧化。小麦低聚肽的抗氧化功能与其含有疏水基团(Glu、Leu、Tyr)或碱性氨基酸(His、Arg、Lys)有关。有研究指出,小麦低聚肽含有丰富的具有抗氧化活性的氨基酸,如谷氨酸、脯氨酸、亮氨酸、蛋氨酸和组氨酸等。由于人体生理活动的复杂性,小麦低聚肽抗氧化活性的具体机理还有待进一步的研究。
4.2调节免疫功能
小麦低聚肽的免疫活性已得到证实,用Alcalase碱性蛋白酶水解小麦蛋白,水解物中含有刺激小鼠体外淋巴细胞增殖作用的活性肽。相关研究对其机理进行了报道,小麦低聚肽含有丰富谷氨酰胺,能够刺激机体淋巴细胞的增殖,增强巨噬细胞的吞噬功能,提高机体抗感染能力,有效提高机体免疫力。小麦低聚肽的免疫活性可能与其含有疏水性氨基酸或碱性氨基酸有关。
4.3降血压
小麦蛋白经蛋白酶水解后产生的小麦低聚肽含有血管紧张素转化酶(ACE),ACE是能够催化水解血管紧张素Ⅰ转化成高血压因子——血管紧张素Ⅱ,也能分解降压物质缓激肽,使其失去活性。小麦低聚肽通过抑制ACE活性可以起到调控血压的作用。有研究在酸性条件下利用蛋白酶水解小麦麦谷蛋白,得到了具有ACE抑制活性的三肽,并采用固相合成法合成了此肽,且同样具有ACE抑制活性。另有研究者用酶解小麦胚蛋白方法生产出了降血压肽。Matsul T采用5种蛋白酶直接水解小麦胚粉提取出降血压肽。
4.4调节血液胆固醇
小麦低聚肽具有调节血液胆固醇的作用。现有研究对大豆低聚肽的降胆固醇作用研究较多,对小麦低聚肽的降胆固醇作用研究相对较少。有研究在观察不同浓度的小麦低聚肽对人肝癌细胞株HepG2胆固醇代谢的影响后得出结论,认为不同浓度的小麦低聚肽均能提升HepG2细胞内LDLR mRNA水平和降低HMGCR mRNA水平,从而起到降低胆固醇的作用。
4.5镇痛作用
小麦低聚肽具有阿片样活性,能够起到镇痛作用,在1979年就发现用胃蛋白酶水解小麦谷蛋白,可获得具有阿片样活性的肽类物质(外啡肽),可有效调节神经,起到镇痛作用。
4.6其他功效
小麦低聚肽还具有抗过敏、抗癌等活性。研究证实,小麦肽具有较高的抗过敏活性、对头敏质酸梅具有较强的抑制作用。研究指出,小麦肽中含有的谷胱甘肽过氧化酶能催化还原有机过氧化物,使体内化学致癌物质失去毒性,进而起到一定的预防癌症的效果。小麦低聚肽中丰富的谷氨酰胺,是优良的谷氨酰胺补充剂,具有调节血糖、抗疲劳、保护大脑、增强记忆力、调节胃肠功能等生物功能。
5玉米低聚肽
玉米低聚肽肽是玉米蛋白经过一系列酶解后的产物,它是由大量小分子量短肽组成(一般分子量集中在1000以下),但这种小分子量短肽组成的低聚肽活性高,可以提供给特殊人群(如婴儿消化功能不健全,老年人等肠道消化吸收功能衰退人群)肠道营养,对术后康复也有辅助治疗功能。
5.1降低血压
血管紧张素转化酶(ACE)是造成血压升高的基础物质,它使血管收缩,引起血压升高,而玉米肽则具有抑制血管紧张素转化酶的活性作用,减轻血管紧张度,产生降压作用。同理,玉米肽也可预防高血压的发生但对血压正常人群无副作用。
5.2醒酒作用
玉米肽能抑制胃对酒精的吸收,增加体内乙醇脱氢酶和乙醛脱氢酶的活性,促进酒精在体内的代谢和排出,具有抑制酒精中毒作用。玉米肽能够通过提高血液中的丙氨酸和亮氨酸的浓度产生稳定的NAD+,有效地降低血液中的乙醇浓度。国外研究玉米肽的学者对玉米肽较为热衷。例如日本学者M.Yamaguchi等通过对原发性高血压大鼠先后灌食玉米肽和乙醇,比较对照样本,发现血液中乙醇及其氧化产物乙醛的含量都明显降低。同样的结果在人体实验中也得到证实,故可作为醒酒产品。
5.3抗氧化作用
玉米肽具有很强的抗氧化性,其抗氧化性类似超氧化歧化酶,玉米肽极易清除超氧阴离子自由基和羟基自由基,并抑制细胞和组织脂质过氧化反应的发生。
5.4其他:玉米低聚肽还具有减肥、抗疲劳、保肝、提高机体免疫力等功能。
6酵母-β葡聚糖
β-葡聚糖(β-glucan)是一种葡萄糖的同聚物,大量存在于微生物、植物以及动物体内。不同来源的β-葡聚糖的葡萄糖单元以不同的方式连接在一起,形成有生物活性的聚合物。Pillemer和Ecker等在20世纪40年代,发现了在酵母细胞中有一种活性物质,它有着免疫刺激的作用。Di Luzio和Riggi到了1960年左右才确定了这一活性物质就是β-1,3-葡聚糖。这几年的很多试验研究都表明,对人体的生理功能非常有益的β-葡聚糖,可以明显地降血糖、降血脂,还可以提高免疫力等,所以β-葡聚糖的开发以及研究现已非常火热。生物活性最高的β-葡聚糖就是酵母β-葡聚糖。酵母是一种重要的食品工业微生物,葡聚糖、蛋白质以及甘露聚糖分别是酵母细胞壁的最内层到最外层,其中位于最内层的葡聚糖就是均一的活性多糖,酵母中的β-葡聚糖是由β-1,3键相连的D-葡萄糖组成的线性骨架以及β-1,6键的分支和主干相连构成,酵母β-葡聚糖跟一般的真菌相比其分支较长[3],酵母β-葡聚糖在很多行业中都有着巨大的商业价值,如食品、医药、化妆品和水产养殖等。
6.1增强免疫
β-葡聚糖的最基本的功能就是有着免疫调节作用,体内及体外的试验研究发现,β-葡聚糖可以刺激先天免疫系统,从而达到抵抗细菌、真菌以及病毒等的能力大大提高。β-葡聚糖可以通过活化T细胞、巨噬细胞以及自然杀伤细胞,还可以刺激T淋巴细胞的分化和活化,影响并激活途径补体的变化,最终达到增强机体细胞和体液免疫的效果。
6.2对肠胃的作用
因为人体内没有降解β-葡聚糖的酶,所以它们有着天然的营养纤维的作用。研究表明,高纤维的饮食可以降低胆固醇,而且减少关节炎等慢性疾病和心脏病的发生率。当β-葡聚糖进入口腔,就会开始吸水膨胀。水溶性的β-葡聚糖又会让食物黏性增加、胃排空的速度减慢,进而增加了进餐时的满足感以及餐后的饱腹感。给大鼠喂了可溶性的纤维后发现,胃排空延迟不但跟β-葡聚糖的黏性有关,而且跟结肠中的代谢产物短链脂肪酸有关。通过动物试验研究发现,β-葡聚糖的膳食纤维可以增加肠道的运输时间,有减慢肠道吸收的作用。在临床试验中还发现,因为水溶性的膳食纤维可以形成的高黏度,不仅可以中和肠道的收缩运动,从而导致其蠕动变慢;还可以刺激肠促胰酶肽(CCK)的释放,CCK有刺激小肠蠕动的作用。另外,可溶性的食物纤维在大肠中发酵得到的SCFA也可以刺激肠道收缩。
6.3促进伤口愈合作用
创伤的修复其本质是内环境稳态的修复,是一个非常复杂的生理过程。正常情况下,创伤的修复是需要不同表型细胞之间的巨噬细胞,成纤维细胞,角质化细胞以及创伤生长因子、基质蛋白和基质修复酶等相互的编排作用。还有相关文献表明,给予局部或者全身β-葡聚糖可以加快伤口的愈合速度,其机理是增加巨噬细胞在创伤处的渗入,从而促进肉芽的生长以及胶原的沉积,同时加强伤处的抗拉强度。
6.4抗凝血作用
人们合成了多种结构确定的多糖的硫酸盐是为了寻找肝素的替代品。通过试验,β-葡聚糖的硫酸盐表现出显著的抗凝血活性。研究人员对β-葡聚糖硫酸盐的构效关系,其分子量以及硫酸盐化作用的程度等做了试验研究后发现,β-葡聚糖抗凝血的决定性因素就是多糖的基本结构以及硫酸盐化的模式。β-葡聚糖的作用方式与肝素不同,它们依靠着自身独特的结构,对抗凝血酶AT-III进行调节,抑制了凝血因子IIa以及Xa的活性,达到特定的干扰着凝血过程的不同阶段。
6.5抗肿瘤作用
研究发现,虽然很多的多糖都具有抗肿瘤的作用,但是目前研究的β-(1,3)葡聚糖和β-(1,4)葡聚糖,以及相关此类多糖在抗肿瘤活性上有明显的优势。同时β-葡聚糖的抗肿瘤和其免疫作用之间有着非常密切的关系,因为多糖体是可以促进细胞激素IL-1、IL-2的分泌,它们可以增加T细胞的数目,增强其作用功能,还可以使体内巨噬细胞的攻击能力增强,使不正常及肿瘤细胞死亡,所以有着防癌抗癌的效果。
6.6抗辐射和抗氧化作用
清除体内的自由基,让巨噬细胞受到辐射后免于受自由基的攻击,使巨噬细胞仍能正常的发挥作用是β-葡聚糖的功效。Pathchen ML等发现,水溶性的葡聚糖可以使被钴-60诱导辐射后的细胞痊愈加快。经过辐射的小鼠经β-(1,3)葡聚糖的治疗,能显著提高恢复能力,增强其骨髓的活力以及脾细胞数量。生物体内的自由基清除剂,对于抗氧化有积极作用的SOD。不同剂量的水溶性的酵母β-(1,3)葡聚糖作用于试验小鼠,它的血清中SOD的活力会随着剂量的增加而增大,研究发现,其呈现出了剂量和效应有着正相关的关系,说明了水溶性的酵母β-(1,3)葡聚糖有着很好的清除自由基的效果,而且注射给药效果比灌胃给药效果要好。
7低聚木糖
低聚木糖也称木寡糖,是以木聚糖为底物通过内切木聚糖酶水解木聚糖的β-1,4糖苷键而得到的以木二糖、木三糖为主要成分的低聚木糖混合物。木二糖的甜度相当于蔗糖的30%,并且低聚木糖的甜度纯正,没有异味。低聚木糖有很强的增殖肠道益生菌的功能,对双歧杆菌、乳酸菌等益生菌有高选择性增殖效果,但对大肠杆菌、肠球菌、梭状芽孢杆菌等病原菌则有明显的抑制作用。体外实验表明,双歧杆菌(如长双歧杆菌、青春双歧杆菌及婴儿双歧杆菌等)均可利用木二糖、木三糖或以木二糖为主要成分的低聚木糖;乳酸菌及其他益生菌也可发酵利用低聚木糖,但大肠杆菌、肠球菌及梭状芽孢杆菌等病原菌却不能利用低聚木糖。此外,大鼠体内实验表明,低聚木糖在肠道内对双歧杆菌也有高选择性增殖效果,不仅可增殖其数量,而且可延长其存活时间。
低聚木糖很难被人体消化分解,唾液、胃液、胰液和小肠液等都几乎不能分解低聚木糖。其能量值近似为零,可在低能量食品中发挥作用。最大限度地满足那些喜欢甜品又担心发胖者的要求。还可供糖尿病人、肥胖病人和高血糖病人食用。另外,低聚木糖具有改善大便性状的功能。摄入低聚木糖后增加了大便中的水分,可改变大便的形态,从而防止便秘的出现。低聚木糖还可以用作抗氧化剂,能够预防氧化胁迫、贫血、动脉硬化、糖尿病、骨质疏松和一些癌症。低聚木糖还被证明有降血脂、抗菌、抗炎、抗过敏的作用。
实施案例1
浓缩乳清蛋白(65.6%)、银耳粉(10.9%)、针叶樱桃粉(10.9%)、小麦低聚肽(3.3%)、玉米低聚肽(3.3%)、酵母-β葡聚糖(1.1%)、低聚木糖(4.3%)、甜菊糖苷(0.6%)。
本实例为常规营养支持,适合各种低蛋白血症、消化吸收功能下降、进食困难以及食欲不振人群。添加甜菊糖苷,赋予产品适当甜味,口感更佳。
实施案例2
浓缩乳清蛋白(60%)、银耳粉(16%)、针叶樱桃粉(11%)、小麦低聚肽(3.5%)、玉米低聚肽(2.8%)、酵母-β葡聚糖(1.4%)、低聚木糖(5.3%)。
本实例适合肥胖或体脂过高人群代餐,即提供充足的营养,又能控制脂肪的摄入。
实施案例3
浓缩乳清蛋白(65.6%)、银耳粉(10.9%)、针叶樱桃粉(10.9%)、小麦低聚肽(3.3%)、玉米低聚肽(3.3%)、酵母-β葡聚糖(1.1%)、低聚木糖(4.3%),复配维生素、矿物元素、甜菊糖苷(0.6%)。
本实例是以本发明配方为核心组分,复合配伍多种维生素(醋酸维生素A、维生素D3、dl-α-醋酸生育酚、盐酸硫胺素、核黄素、盐酸吡哆醇、氰钴胺、烟酰胺、叶酸、D-泛酸钙)、碳酸镁、乙二胺四乙酸铁钠、葡萄糖酸锌、磷酸氢钙,制成全营养类产品,可完全替代其他食物,补充优质蛋白、碳水化合物、维生素、矿物元素,并提供各种有助于增强免疫力、降低感染和并发症风险的健康因子。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (6)
1.一种浓缩乳清蛋白复合低聚肽营养粉,其特征在于:主要包括如下以重量份计的原料:浓缩乳清蛋白55~70份、银耳粉7~12份、针叶樱桃粉7~12份、小麦低聚肽2~6份、玉米低聚肽2~6份、酵母-β葡聚糖0.5~1.7份、低聚木糖3~6份。
2.根据权利要求1所述的浓缩乳清蛋白复合低聚肽营养粉,其特征在于:主要包括如下以重量百分比计的原料:浓缩乳清蛋白65.6%、银耳粉10.9%、针叶樱桃粉10.9%、小麦低聚肽3.3%、玉米低聚肽3.3%、酵母-β葡聚糖1.1%、低聚木糖4.3%、甜菊糖苷0.6%。
3.根据权利要求1所述的浓缩乳清蛋白复合低聚肽营养粉,其特征在于:主要包括如下以重量百分比计的原料:浓缩乳清蛋白60%、银耳粉16%、针叶樱桃粉11%、小麦低聚肽3.5%、玉米低聚肽2.8%、酵母-β葡聚糖1.4%、低聚木糖5.3%。
4.根据权利要求1所述的浓缩乳清蛋白复合低聚肽营养粉,其特征在于:主要包括如下以重量百分比计的原料:浓缩乳清蛋白65.6%、银耳粉10.9%、针叶樱桃粉10.9%、小麦低聚肽3.3%、玉米低聚肽3.3%、酵母-β葡聚糖1.1%、低聚木糖4.3%,复配维生素、矿物元素、甜菊糖苷0.6%。
5.根据权利要求1或2或3所述的浓缩乳清蛋白复合低聚肽营养粉,其特征在于:所述的浓缩乳清蛋白是将乳清通过低温超滤和喷雾干燥制成的天然乳清蛋白浓缩物。
6.根据权利要求1或2或3所述的浓缩乳清蛋白复合低聚肽营养粉,其特征在于:所述的小麦低聚肽是以谷朊粉为原料、经过定向酶切及特定的小肽分离技术获得的小分子多肽类混合物,主要成分是由2~6个氨基酸分子构成的小肽。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710934686.5A CN107890117A (zh) | 2017-10-10 | 2017-10-10 | 一种浓缩乳清蛋白复合低聚肽营养粉 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710934686.5A CN107890117A (zh) | 2017-10-10 | 2017-10-10 | 一种浓缩乳清蛋白复合低聚肽营养粉 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107890117A true CN107890117A (zh) | 2018-04-10 |
Family
ID=61803496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710934686.5A Pending CN107890117A (zh) | 2017-10-10 | 2017-10-10 | 一种浓缩乳清蛋白复合低聚肽营养粉 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107890117A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109329948A (zh) * | 2018-12-05 | 2019-02-15 | 北京斯利安药业有限公司 | 一种具有增强免疫力功能的组合物及其应用 |
CN112890066A (zh) * | 2021-03-16 | 2021-06-04 | 江西省科学院生物资源研究所 | 一种调血脂、抗疲劳、增强免疫力的固体饮料及其应用 |
CN114916677A (zh) * | 2022-04-18 | 2022-08-19 | 沈阳药大生物科技有限公司 | 一种改善细胞健康状况的低聚肽组合物 |
CN115521963A (zh) * | 2022-10-28 | 2022-12-27 | 华南理工大学 | 一种谷氨酰胺肽及其制备方法与应用 |
CN115918914A (zh) * | 2022-12-01 | 2023-04-07 | 宝健(北京)生物技术有限公司 | 一种含复合蛋白的口服营养补充剂,制备及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496579A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种供肿瘤患者食用含短肽的特殊膳食用食品配方 |
CN104605353A (zh) * | 2015-01-27 | 2015-05-13 | 南阳市新天地生物科技有限公司 | 适用于手术后肿瘤患者食用的配方食品及其制备方法 |
CN105077270A (zh) * | 2015-07-16 | 2015-11-25 | 上海冬泽特医食品有限公司 | 一种营养强化复合粉、其制备方法及用途 |
CN107173732A (zh) * | 2017-05-31 | 2017-09-19 | 江苏朸健生命科技发展有限公司 | 一种适用于肿瘤营养的复合营养粉及其制备方法 |
-
2017
- 2017-10-10 CN CN201710934686.5A patent/CN107890117A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496579A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种供肿瘤患者食用含短肽的特殊膳食用食品配方 |
CN104605353A (zh) * | 2015-01-27 | 2015-05-13 | 南阳市新天地生物科技有限公司 | 适用于手术后肿瘤患者食用的配方食品及其制备方法 |
CN105077270A (zh) * | 2015-07-16 | 2015-11-25 | 上海冬泽特医食品有限公司 | 一种营养强化复合粉、其制备方法及用途 |
CN107173732A (zh) * | 2017-05-31 | 2017-09-19 | 江苏朸健生命科技发展有限公司 | 一种适用于肿瘤营养的复合营养粉及其制备方法 |
Non-Patent Citations (3)
Title |
---|
潘兴昌等: "食源性低聚肽与特殊膳食食品的开发", 《营养与食品-健康中国高级论坛II论文集》 * |
阎世英: "《酵素决定健康》", 31 January 2016, 北京医药科技出版社 * |
齐玉梅等: "《特殊医学用途配方食品临床应用参考目录》", 31 August 2017, 中国医药科技出版社 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109329948A (zh) * | 2018-12-05 | 2019-02-15 | 北京斯利安药业有限公司 | 一种具有增强免疫力功能的组合物及其应用 |
CN109329948B (zh) * | 2018-12-05 | 2022-04-01 | 北京斯利安药业有限公司 | 一种具有增强免疫力功能的组合物及其应用 |
CN112890066A (zh) * | 2021-03-16 | 2021-06-04 | 江西省科学院生物资源研究所 | 一种调血脂、抗疲劳、增强免疫力的固体饮料及其应用 |
CN114916677A (zh) * | 2022-04-18 | 2022-08-19 | 沈阳药大生物科技有限公司 | 一种改善细胞健康状况的低聚肽组合物 |
CN115521963A (zh) * | 2022-10-28 | 2022-12-27 | 华南理工大学 | 一种谷氨酰胺肽及其制备方法与应用 |
CN115918914A (zh) * | 2022-12-01 | 2023-04-07 | 宝健(北京)生物技术有限公司 | 一种含复合蛋白的口服营养补充剂,制备及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108112996B (zh) | 一种控制2型糖尿病人群高血糖和提高免疫力的营养组合物 | |
CN107890117A (zh) | 一种浓缩乳清蛋白复合低聚肽营养粉 | |
CN108685100B (zh) | 一种复合短肽粉配方及其制备方法 | |
CN101077143A (zh) | 全营养绿色保健杂面系列挂面和方便面及其制做方法 | |
CN111670997A (zh) | 增强免疫复合蛋白肽酶解液的制备方法、增强免疫复合蛋白肽饮品及其制备方法 | |
CN110771825A (zh) | 一种用于减脂、降血糖、降血压和降血脂的综合营养粉及其制备方法 | |
KR101539382B1 (ko) | 장 기능 개선 및 배변 촉진용 식품 조성물 | |
CN102488278A (zh) | 一种具有双功能保健作用的复合真菌营养液 | |
CN104207150A (zh) | 大豆肽真菌多糖口服液及其制备方法 | |
CN106578801A (zh) | 一种具有降糖作用的综合酵素粉及其制备方法 | |
CN104605353A (zh) | 适用于手术后肿瘤患者食用的配方食品及其制备方法 | |
CN101569410A (zh) | 肿瘤患者用的特膳营养食品 | |
CN106360739A (zh) | 一种调节血压、降低血糖、补充营养的组合物 | |
CN106858595A (zh) | 一种烧伤专用型临床营养配方及其制备方法 | |
CN105380271A (zh) | 无添加剂全籽粒绿豆复合营养粉及其生产方法 | |
CN107279978A (zh) | 一种适用于肿瘤病人的特殊医学用途配方食品 | |
JP2002272414A (ja) | 大腸癌発症抑制栄養補助組成物並びに製造方法 | |
CN109329902A (zh) | 一种儿童白血病专用型临床营养配方及其制备方法 | |
CN111543605A (zh) | 一种四高或肥胖人群用综合营养粉 | |
CN108308597A (zh) | 一种营养不良专用型临床营养配方及其制备方法 | |
CN108576827A (zh) | 围手术期营养食品 | |
CN108783465A (zh) | 一种具有肿瘤治疗功能的营养配方产品 | |
CN108378296A (zh) | 围手术期营养食品 | |
CN103561756A (zh) | 用于预防以及/或者改善癌症引起的非可逆性的代谢紊乱的组合物 | |
CN106136235A (zh) | 一种肿瘤病人特殊医学用途配方食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180410 |